Skip to main content
CRESCENT BIOPHARMA, INC. logo

CRESCENT BIOPHARMA, INC. — Investor Relations & Filings

Ticker · CBIO ISIN · US38000Q1022 US Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US CBIO

About CRESCENT BIOPHARMA, INC.

https://www.crescentbiopharma.com/

Crescent Biopharma, Inc. is a biopharmaceutical company dedicated to researching and developing the next wave of cancer therapies. The company's vision is to build a world-leading oncology organization by focusing on revolutionary shifts in the field to transform cancer treatment. Its strategy involves advancing a pipeline of therapies with multiple modalities, including precision-engineered small molecule therapeutics, designed to address cancer on various fronts. Crescent Biopharma aims to deliver a new standard of care for people living with cancer through its innovative pipeline.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-06-03 English
8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the year ended December 31, 2025. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 4188 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The document is primarily an announcement of financial results via a press release, not the full earnings release or annual report itself. Therefore, the best classification is Earnings Release (ER), as it corresponds to the initial announcement of quarterly or periodical financial results (key highlights only).
2026-02-26 English
10-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
Annual Report FY 2025
2026-02-26 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-05 English
424B3 Filing
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the resale of ordinary shares by selling securityholders. It includes extensive information about the securities offered, risk factors, management discussion and analysis, business overview, management, executive compensation, principal shareholders, share capital description, plan of distribution, legal matters, and consolidated financial statements. The document is clearly a registration and offering prospectus for securities resale, which is a type of capital markets financing document. It is not an annual report, earnings release, or any other type of report but rather a capital/financing update related to share resale and private placement shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2026-01-15 English
S-1 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the registration of securities to be sold by selling securityholders. The document includes a preliminary prospectus, details about the securities offered, risk factors, management discussion and analysis, business description, management, executive compensation, principal shareholders, and legal matters. This type of filing is related to capital raising activities and securities registration, not an annual report, earnings release, or other financial report. The Form S-1 is a registration statement used for initial public offerings or other securities offerings. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the offering, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear identification of the form and content.
2026-01-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.